- Home
- ONCO vs PPBT Comparison
ONCO vs PPBT Comparison
Compare ONCO & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | PPBT |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | Israel |
| Employees | N/A | 10 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ONCO | PPBT |
|---|---|---|
| Price | $0.81 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 192.6K | 25.4K |
| Earning Date | 06-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $815,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.41 |
| 52 Week High | $6.73 | $5.18 |
Technical Indicators
Market Signals| Indicator | ONCO | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 48.09 |
| Support Level | $0.62 | $1.38 |
| Resistance Level | $0.86 | $1.85 |
| Average True Range (ATR) | 0.09 | 0.14 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 47.82 | 68.74 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.